Experimental Endoscopic Gut Reset Procedure Shows Potential to Prevent Weight Regain After GLP-1 Cessation

New REMAIN-1 trial data shows duodenal mucosal resurfacing helps patients keep weight off after stopping GLP-1 medications like tirzepatide.

By: AXL Media

Published: Apr 24, 2026, 5:53 AM EDT

Source: Information for this report was sourced from Digestive Disease Week

Addressing the Weight Rebound Crisis in Obesity Care

As the use of glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and tirzepatide continues to rise, healthcare providers are facing a secondary challenge: weight regain. Statistics indicate that approximately 70% of patients eventually discontinue these medications due to cost, side effects, or a desire to avoid lifelong drug dependency. According to data from Digestive Disease Week 2026, most patients who stop these therapies regain their lost weight within 18 months, often losing the metabolic benefits associated with their initial success.

The Role of the Duodenum in Metabolic Resetting

Researchers are investigating duodenal mucosal resurfacing (DMR) as a one-time solution to this problem. The procedure involves the use of targeted hydrothermal energy to ablate the inner mucosal lining of the duodenum, which is the first section of the small intestine. Scientists believe that chronic high-fat and high-sugar diets cause this lining to thicken, which disrupts how the gut signals the rest of the body to process nutrients and insulin. By rejuvenating this tissue, the procedure aims to reset the body's metabolic signaling to favor weight maintenance rather than regain.

Promising Results from the REMAIN-1 Trial

The findings presented by Dr. Shelby Sullivan of Dartmouth Health highlight significant differences between patients who received the actual DMR procedure and those who underwent a sham version. In a midpoint cohort of 45 participants, all of whom had lost at least 15% of their body weight using tirzepatide, the sham group regained 40% more weight just six months after stopping the drug. In contrast, patients who received a higher "dose" of the procedure—meaning more tissue was resurfaced—maintained more than 80% of their weight loss, regaining only about 7 pounds on average.